Page last updated: 2024-11-13

acy-1215

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ricolinostat: an HDAC6 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53340666
CHEMBL ID2364628
CHEBI ID95073
SCHEMBL ID574580
MeSH IDM0573810

Synonyms (59)

Synonym
acy-1215
1316214-52-4
rocilinostat (acy-1215)
wkt909c62b ,
unii-wkt909c62b
2-(diphenylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
rocilinostat
5-pyrimidinecarboxamide, 2-(diphenylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)-
ricolinostat [usan:inn]
acy-63
ricolinostat
HY-16026
CS-0965
NCGC00345802-01
ricolinostat [who-dd]
2-(diphenylamino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
ricolinostat [usan]
ricolinostat [inn]
S8001
gtpl7010
n-[7-(hydroxyamino)-7-oxoheptyl]-2-(n-phenylanilino)pyrimidine-5-carboxamide
SCHEMBL574580
CHEMBL2364628
us8609678, 2-(diphenylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide [26]
bdbm50439674
MLS006011181
smr004702950
AKOS024259260
2-(diphenylamino)-n-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide
D10661
ricolinostat (usan/inn)
AC-30258
DTXSID40157148
J-690127
EX-A139
CHEBI:95073
HMS3653F17
AS-73344
mfcd22666356
NCGC00345802-05
acy1215
7-{[2-(diphenylamino)pyrimidin-5-yl]formamido}-n-hydroxyheptanamide
SW219836-1
DB12376
ah4 ,
ricolinostat (acy-1215)
BCP06028
Q27088553
5-pyrimidinecarboxamide, 2-(diphenylamino)-n-[7-(hydroxyamino)-7-oxoheptyl]-
SB17054
HMS3426C09
HMS3886L21
AMY38185
CCG-269054
SY096614
nsc-767952
nsc767952
acy 1215
BA164806

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Most adverse events were grade 1-2, including diarrhea (57%), nausea (57%), and fatigue (43%)."( First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Amengual, JE; Cremers, S; Jones, S; Lichtenstein, R; Lue, JK; Ma, H; Sawas, A; Shah, B, 2021
)
0.89
"ACY-1215 is an oral selective HDAC6 inhibitor that was safe in patients with relapsed and refractory lymphoid malignancies and led to disease stabilization in half of the evaluable patients."( First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Amengual, JE; Cremers, S; Jones, S; Lichtenstein, R; Lue, JK; Ma, H; Sawas, A; Shah, B, 2021
)
2.33

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 hours after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochemistry and Western blot analysis."( Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Anderson, KC; Bradner, J; Canavese, M; Cirstea, D; Eda, H; Hideshima, T; Jarpe, M; Jones, SS; Kung, AL; Mazitschek, R; Ogier, WC; Raje, N; Rodig, S; Santo, L; Scullen, T; Tamang, D; Tseng, JC; van Duzer, JH; Yang, M, 2012
)
0.85
" This novel method has been applied to a pharmacokinetic study in mice."( Sensitive method for the determination of rocilinostat in small volume mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice.
Bhamidipati, RK; Devaraj, VC; Dewang, P; Dixit, A; Gupta, M; Hallur, MS; Mullangi, R; Rajagopal, S; Zainuddin, M, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" In the present study, we investigated the preclinical activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM."( Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Anderson, KC; Bradner, J; Canavese, M; Cirstea, D; Eda, H; Hideshima, T; Jarpe, M; Jones, SS; Kung, AL; Mazitschek, R; Ogier, WC; Raje, N; Rodig, S; Santo, L; Scullen, T; Tamang, D; Tseng, JC; van Duzer, JH; Yang, M, 2012
)
0.83

Bioavailability

ExcerptReferenceRelevance
" It has a good pharmacokinetic profile with oral bioavailability of 33%."( Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
Chang, CY; Chang, JY; Chen, MC; Cheng, YC; Kuo, CC; Lee, HY; Liou, JP; Liu, JF; Liu, YM; Pan, SL; Shen, PJ; Tsai, AC; Wang, JC; Yeh, TK, 2014
)
0.4
" 23bb has a good pharmacokinetic profile with oral bioavailability of 47."( Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Cao, D; Chen, L; Chen, X; Liu, Z; Long, C; Ma, L; Niu, T; Tang, M; Wang, F; Wang, T; Wang, X; Xiang, W; Yang, Z; Yi, Y; You, J, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Flow cytometry was used to determine a suitable treatment dosage of ACY-1215 on lipopolysaccharide (LPS)-activated macrophages. 50% of patients treated on a twice-daily dosing schedule.

ExcerptRelevanceReference
"Flow cytometry was used to determine a suitable treatment dosage of ACY-1215 on lipopolysaccharide (LPS)-activated macrophages for the present study."( Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways.
Gong, ZJ; Jiao, FZ; Wang, LW; Wang, Y; Yang, F; Zhang, HY; Zhang, WB, 2019
)
0.75
" ACY-1215 is well tolerated and led to disease stabilization in 50% of patients treated on a twice-daily dosing schedule."( First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Amengual, JE; Cremers, S; Jones, S; Lichtenstein, R; Lue, JK; Ma, H; Sawas, A; Shah, B, 2021
)
1.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidinecarboxylic acidAny pyrimidine that bears one or more carboxylic acid substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency9.30050.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency5.30810.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Interferon betaHomo sapiens (human)Potency9.30050.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone deacetylase 6Danio rerio (zebrafish)IC50 (µMol)0.09000.09000.09000.0900AID1703056
Histone deacetylase 3Homo sapiens (human)IC50 (µMol)0.06300.00040.619610.0000AID1282239; AID1384208; AID1390012; AID1473146; AID1525779; AID1703044; AID1739974; AID1783134; AID1813992; AID1814038; AID1845770; AID1864666; AID1864731; AID1876341; AID1882274; AID1901761; AID767941
Histone deacetylase 3Homo sapiens (human)Ki0.12300.00020.42378.1900AID1864726
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)10.00000.00051.28547.6500AID1441630; AID1441631
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)25.00000.00050.939410.0000AID1363797; AID1363798; AID1363799
Histone deacetylase 4Homo sapiens (human)IC50 (µMol)4.90910.00061.052610.0000AID1282240; AID1473147; AID1578487; AID1679282; AID1703050; AID1739975; AID1783135; AID1845771; AID1864667; AID1882275; AID767940
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)0.08610.00010.55439.9000AID1141786; AID1282229; AID1384206; AID1390010; AID1428506; AID1473144; AID1525777; AID1535339; AID1537570; AID1558032; AID1679290; AID1723742; AID1739972; AID1753636; AID1783132; AID1845768; AID1864664; AID1864729; AID1882272; AID1890307; AID1917530; AID767943
Histone deacetylase 1Homo sapiens (human)Ki0.07400.00000.49888.1900AID1864674
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)IC50 (µMol)1.00000.50003.848110.0000AID1679275
Histone deacetylase 7Homo sapiens (human)IC50 (µMol)2.66670.00071.02609.9000AID1282242; AID1473149; AID1679280; AID1739977; AID1783138; AID1845774; AID1864670; AID1882278; AID767936
Histone deacetylase 2Homo sapiens (human)IC50 (µMol)0.11160.00010.72219.9700AID1141787; AID1282238; AID1384207; AID1390011; AID1428507; AID1473145; AID1525778; AID1578486; AID1679289; AID1703049; AID1739973; AID1783133; AID1845769; AID1864665; AID1864730; AID1882273; AID767942
Histone deacetylase 2Homo sapiens (human)Ki0.20400.00000.47098.1900AID1864725
Polyamine deacetylase HDAC10Homo sapiens (human)IC50 (µMol)2.97620.00050.72459.9000AID1282244; AID1587859; AID1587860; AID767934
Histone deacetylase 11 Homo sapiens (human)IC50 (µMol)4.44440.00030.92989.9000AID1282245; AID1473153; AID1679278; AID1703047; AID1739981; AID1876344; AID1882281; AID1901764; AID1917542
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)IC50 (µMol)5.50000.00601.62509.0000AID1473154; AID1679277
Histone deacetylase 8Homo sapiens (human)IC50 (µMol)0.81500.00070.99479.9000AID1282231; AID1390014; AID1473150; AID1525780; AID1679274; AID1703046; AID1739983; AID1783139; AID1845775; AID1864671; AID1876343; AID1882279; AID1901763; AID1917541; AID767937
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)0.08400.00000.53769.9000AID1141788; AID1282230; AID1384209; AID1390013; AID1428508; AID1473143; AID1525776; AID1532657; AID1535340; AID1537571; AID1558033; AID1617397; AID1679288; AID1703045; AID1718995; AID1723743; AID1739979; AID1753635; AID1783137; AID1813993; AID1814039; AID1819859; AID1845773; AID1864669; AID1864732; AID1876342; AID1882260; AID1882277; AID1890308; AID1895832; AID1901762; AID1917529; AID1917933; AID767938
Histone deacetylase 6Homo sapiens (human)Ki0.00100.00010.41568.1900AID1864727
Histone deacetylase 9Homo sapiens (human)IC50 (µMol)7.12500.00050.94139.9000AID1282243; AID1473151; AID1679279; AID1739978; AID1845776; AID1864672; AID1882280; AID767935
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)4.66670.00070.961010.0000AID1282241; AID1473148; AID1679281; AID1739976; AID1783136; AID1845772; AID1864668; AID1882276; AID767939
Nuclear receptor corepressor 2Homo sapiens (human)IC50 (µMol)0.04630.00170.59528.0000AID1390012; AID1473146; AID1739974
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC5014.79500.128015.173038.6100AID1259418; AID1259420
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (347)

Processvia Protein(s)Taxonomy
negative regulation of myotube differentiationHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
establishment of mitotic spindle orientationHistone deacetylase 3Homo sapiens (human)
in utero embryonic developmentHistone deacetylase 3Homo sapiens (human)
positive regulation of protein phosphorylationHistone deacetylase 3Homo sapiens (human)
chromatin organizationHistone deacetylase 3Homo sapiens (human)
transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
protein deacetylationHistone deacetylase 3Homo sapiens (human)
regulation of mitotic cell cycleHistone deacetylase 3Homo sapiens (human)
positive regulation of protein ubiquitinationHistone deacetylase 3Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 3Homo sapiens (human)
positive regulation of TOR signalingHistone deacetylase 3Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
regulation of multicellular organism growthHistone deacetylase 3Homo sapiens (human)
positive regulation of protein import into nucleusHistone deacetylase 3Homo sapiens (human)
regulation of circadian rhythmHistone deacetylase 3Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
negative regulation of JNK cascadeHistone deacetylase 3Homo sapiens (human)
spindle assemblyHistone deacetylase 3Homo sapiens (human)
establishment of skin barrierHistone deacetylase 3Homo sapiens (human)
cellular response to fluid shear stressHistone deacetylase 3Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone deacetylase 3Homo sapiens (human)
DNA repair-dependent chromatin remodelingHistone deacetylase 3Homo sapiens (human)
cornified envelope assemblyHistone deacetylase 3Homo sapiens (human)
negative regulation of cardiac muscle cell differentiationHistone deacetylase 3Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
chromatin remodelingHistone deacetylase 4Homo sapiens (human)
protein deacetylationHistone deacetylase 4Homo sapiens (human)
inflammatory responseHistone deacetylase 4Homo sapiens (human)
nervous system developmentHistone deacetylase 4Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 4Homo sapiens (human)
response to denervation involved in regulation of muscle adaptationHistone deacetylase 4Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone deacetylase 4Homo sapiens (human)
protein sumoylationHistone deacetylase 4Homo sapiens (human)
B cell differentiationHistone deacetylase 4Homo sapiens (human)
positive regulation of protein sumoylationHistone deacetylase 4Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 4Homo sapiens (human)
B cell activationHistone deacetylase 4Homo sapiens (human)
regulation of protein bindingHistone deacetylase 4Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 4Homo sapiens (human)
negative regulation of glycolytic processHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
type I interferon-mediated signaling pathwayHistone deacetylase 4Homo sapiens (human)
response to interleukin-1Histone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 7Homo sapiens (human)
vasculogenesisHistone deacetylase 7Homo sapiens (human)
chromatin remodelingHistone deacetylase 7Homo sapiens (human)
protein deacetylationHistone deacetylase 7Homo sapiens (human)
cell-cell junction assemblyHistone deacetylase 7Homo sapiens (human)
protein sumoylationHistone deacetylase 7Homo sapiens (human)
negative regulation of interleukin-2 productionHistone deacetylase 7Homo sapiens (human)
negative regulation of osteoblast differentiationHistone deacetylase 7Homo sapiens (human)
regulation of mRNA processingHistone deacetylase 7Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 7Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionHistone deacetylase 7Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
response to amphetamineHistone deacetylase 2Homo sapiens (human)
cardiac muscle hypertrophyHistone deacetylase 2Homo sapiens (human)
chromatin remodelingHistone deacetylase 2Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 2Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 2Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 2Homo sapiens (human)
negative regulation of neuron projection developmentHistone deacetylase 2Homo sapiens (human)
dendrite developmentHistone deacetylase 2Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 2Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 2Homo sapiens (human)
response to caffeineHistone deacetylase 2Homo sapiens (human)
heterochromatin formationHistone deacetylase 2Homo sapiens (human)
response to lipopolysaccharideHistone deacetylase 2Homo sapiens (human)
positive regulation of interleukin-1 productionHistone deacetylase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHistone deacetylase 2Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 2Homo sapiens (human)
positive regulation of collagen biosynthetic processHistone deacetylase 2Homo sapiens (human)
cellular response to heatHistone deacetylase 2Homo sapiens (human)
response to nicotineHistone deacetylase 2Homo sapiens (human)
protein modification processHistone deacetylase 2Homo sapiens (human)
response to cocaineHistone deacetylase 2Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHistone deacetylase 2Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 2Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 2Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of MHC class II biosynthetic processHistone deacetylase 2Homo sapiens (human)
positive regulation of proteolysisHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
behavioral response to ethanolHistone deacetylase 2Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 2Homo sapiens (human)
response to hyperoxiaHistone deacetylase 2Homo sapiens (human)
hair follicle placode formationHistone deacetylase 2Homo sapiens (human)
negative regulation of dendritic spine developmentHistone deacetylase 2Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 2Homo sapiens (human)
fungiform papilla formationHistone deacetylase 2Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 2Homo sapiens (human)
cellular response to retinoic acidHistone deacetylase 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone deacetylase 2Homo sapiens (human)
positive regulation of male mating behaviorHistone deacetylase 2Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
cellular response to dopamineHistone deacetylase 2Homo sapiens (human)
response to amyloid-betaHistone deacetylase 2Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 2Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolyamine deacetylase HDAC10Homo sapiens (human)
DNA repairPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationPolyamine deacetylase HDAC10Homo sapiens (human)
regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
macroautophagyPolyamine deacetylase HDAC10Homo sapiens (human)
positive regulation of mismatch repairPolyamine deacetylase HDAC10Homo sapiens (human)
homologous recombinationPolyamine deacetylase HDAC10Homo sapiens (human)
negative regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
polyamine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
spermidine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
epigenetic regulation of gene expressionPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationHistone deacetylase 11 Homo sapiens (human)
oligodendrocyte developmentHistone deacetylase 11 Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 11 Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of cytokine productionHistone deacetylase 9Homo sapiens (human)
response to amphetamineHistone deacetylase 9Homo sapiens (human)
inflammatory responseHistone deacetylase 9Homo sapiens (human)
heart developmentHistone deacetylase 9Homo sapiens (human)
neuron differentiationHistone deacetylase 9Homo sapiens (human)
B cell differentiationHistone deacetylase 9Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 9Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 9Homo sapiens (human)
B cell activationHistone deacetylase 9Homo sapiens (human)
cholesterol homeostasisHistone deacetylase 9Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 9Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 9Homo sapiens (human)
regulation of skeletal muscle fiber developmentHistone deacetylase 9Homo sapiens (human)
regulation of striated muscle cell differentiationHistone deacetylase 9Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor corepressor 2Homo sapiens (human)
lactationNuclear receptor corepressor 2Homo sapiens (human)
response to organonitrogen compoundNuclear receptor corepressor 2Homo sapiens (human)
regulation of cellular ketone metabolic processNuclear receptor corepressor 2Homo sapiens (human)
cerebellum developmentNuclear receptor corepressor 2Homo sapiens (human)
response to estradiolNuclear receptor corepressor 2Homo sapiens (human)
estrous cycleNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of miRNA transcriptionNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (96)

Processvia Protein(s)Taxonomy
transcription corepressor bindingHistone deacetylase 3Homo sapiens (human)
chromatin bindingHistone deacetylase 3Homo sapiens (human)
transcription corepressor activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase activityHistone deacetylase 3Homo sapiens (human)
protein bindingHistone deacetylase 3Homo sapiens (human)
enzyme bindingHistone deacetylase 3Homo sapiens (human)
cyclin bindingHistone deacetylase 3Homo sapiens (human)
chromatin DNA bindingHistone deacetylase 3Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 3Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 3Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 3Homo sapiens (human)
protein decrotonylase activityHistone deacetylase 3Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 3Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 4Homo sapiens (human)
histone bindingHistone deacetylase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase activityHistone deacetylase 4Homo sapiens (human)
protein bindingHistone deacetylase 4Homo sapiens (human)
zinc ion bindingHistone deacetylase 4Homo sapiens (human)
SUMO transferase activityHistone deacetylase 4Homo sapiens (human)
potassium ion bindingHistone deacetylase 4Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 4Homo sapiens (human)
identical protein bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 4Homo sapiens (human)
molecular adaptor activityHistone deacetylase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingHistone deacetylase 7Homo sapiens (human)
transcription corepressor activityHistone deacetylase 7Homo sapiens (human)
histone deacetylase activityHistone deacetylase 7Homo sapiens (human)
protein kinase C bindingHistone deacetylase 7Homo sapiens (human)
protein bindingHistone deacetylase 7Homo sapiens (human)
SUMO transferase activityHistone deacetylase 7Homo sapiens (human)
protein kinase bindingHistone deacetylase 7Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 7Homo sapiens (human)
metal ion bindingHistone deacetylase 7Homo sapiens (human)
14-3-3 protein bindingHistone deacetylase 7Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 7Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 2Homo sapiens (human)
chromatin bindingHistone deacetylase 2Homo sapiens (human)
RNA bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 2Homo sapiens (human)
protein bindingHistone deacetylase 2Homo sapiens (human)
enzyme bindingHistone deacetylase 2Homo sapiens (human)
heat shock protein bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 2Homo sapiens (human)
histone bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 2Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 2Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 2Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 2Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
protein bindingPolyamine deacetylase HDAC10Homo sapiens (human)
zinc ion bindingPolyamine deacetylase HDAC10Homo sapiens (human)
deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
enzyme bindingPolyamine deacetylase HDAC10Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase bindingPolyamine deacetylase HDAC10Homo sapiens (human)
acetylputrescine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
acetylspermidine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityHistone deacetylase 11 Homo sapiens (human)
protein bindingHistone deacetylase 11 Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 11 Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein kinase C bindingHistone deacetylase 9Homo sapiens (human)
protein bindingHistone deacetylase 9Homo sapiens (human)
histone H3K14 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H3K9 deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H4K16 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 9Homo sapiens (human)
metal ion bindingHistone deacetylase 9Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA bindingNuclear receptor corepressor 2Homo sapiens (human)
chromatin bindingNuclear receptor corepressor 2Homo sapiens (human)
transcription corepressor activityNuclear receptor corepressor 2Homo sapiens (human)
Notch bindingNuclear receptor corepressor 2Homo sapiens (human)
protein bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
histone deacetylase bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (70)

Processvia Protein(s)Taxonomy
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Homo sapiens (human)
cytoplasmHistone deacetylase 3Homo sapiens (human)
Golgi apparatusHistone deacetylase 3Homo sapiens (human)
cytosolHistone deacetylase 3Homo sapiens (human)
plasma membraneHistone deacetylase 3Homo sapiens (human)
mitotic spindleHistone deacetylase 3Homo sapiens (human)
histone deacetylase complexHistone deacetylase 3Homo sapiens (human)
transcription repressor complexHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
nucleusHistone deacetylase 4Homo sapiens (human)
nucleoplasmHistone deacetylase 4Homo sapiens (human)
cytoplasmHistone deacetylase 4Homo sapiens (human)
cytosolHistone deacetylase 4Homo sapiens (human)
nuclear speckHistone deacetylase 4Homo sapiens (human)
histone deacetylase complexHistone deacetylase 4Homo sapiens (human)
chromatinHistone deacetylase 4Homo sapiens (human)
transcription repressor complexHistone deacetylase 4Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusHistone deacetylase 7Homo sapiens (human)
nucleoplasmHistone deacetylase 7Homo sapiens (human)
cytoplasmHistone deacetylase 7Homo sapiens (human)
cytosolHistone deacetylase 7Homo sapiens (human)
chromosome, telomeric regionHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleoplasmHistone deacetylase 2Homo sapiens (human)
cytoplasmHistone deacetylase 2Homo sapiens (human)
NuRD complexHistone deacetylase 2Homo sapiens (human)
Sin3-type complexHistone deacetylase 2Homo sapiens (human)
histone deacetylase complexHistone deacetylase 2Homo sapiens (human)
chromatinHistone deacetylase 2Homo sapiens (human)
protein-containing complexHistone deacetylase 2Homo sapiens (human)
ESC/E(Z) complexHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleusPolyamine deacetylase HDAC10Homo sapiens (human)
nucleoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytosolPolyamine deacetylase HDAC10Homo sapiens (human)
intracellular membrane-bounded organellePolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase complexPolyamine deacetylase HDAC10Homo sapiens (human)
nucleusHistone deacetylase 11 Homo sapiens (human)
plasma membraneHistone deacetylase 11 Homo sapiens (human)
histone deacetylase complexHistone deacetylase 11 Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
nucleusHistone deacetylase 9Homo sapiens (human)
nucleoplasmHistone deacetylase 9Homo sapiens (human)
cytoplasmHistone deacetylase 9Homo sapiens (human)
histone deacetylase complexHistone deacetylase 9Homo sapiens (human)
transcription regulator complexHistone deacetylase 9Homo sapiens (human)
histone methyltransferase complexHistone deacetylase 9Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
nucleusNuclear receptor corepressor 2Homo sapiens (human)
nucleoplasmNuclear receptor corepressor 2Homo sapiens (human)
membraneNuclear receptor corepressor 2Homo sapiens (human)
nuclear matrixNuclear receptor corepressor 2Homo sapiens (human)
nuclear bodyNuclear receptor corepressor 2Homo sapiens (human)
chromatinNuclear receptor corepressor 2Homo sapiens (human)
transcription repressor complexNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (391)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1473216Antiproliferative activity against human NCI-H929 cells after 48 hrs by SRB assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1882276Inhibition of HDAC5 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1876341Inhibition of recombinant full length human HDAC3 expressed in insect Sf9 cells by EMSA analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1363811Cytotoxicity against imatinib-resistant human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1864673Inhibition of HDAC11(unknown origin) preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1832809Anticancer activity against human K562 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1703041Cytotoxicity against human MV4-11 cells measured after 72 hrs by spectrophotometer method2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1814039Inhibition of HDAC6 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate and trypsin addition by microplate reader based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1282241Inhibition of recombinant HDAC5 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1617400Selectivity ratio of IC50 for C-terminal His-tagged human HDAC3 (1 to 428 residues)/N-terminal GST tagged human NCOR2 (395 to 489) expressed in baculovirus infected sf9 insect cells to human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1832830Induction of apoptosis in human K562 cells assessed as increase cleaved PARP expression measured after 24 to 72 hrs by Western blot analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1355700Cell cycle arrest in human HEL cells assessed as accumulation at G1 phase at 1 to 10 uM after 48 hrs propidium iodide staining based flow cytometry2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1282239Inhibition of recombinant HDAC3 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1617403Stability in human plasma assessed as parent compound remaining at 100 uM after 4 hrs by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1282254Cytotoxicity against human Ramos cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1703049Inhibition of recombinant full length human HDAC2 expressed in SF9 baculovirus using FAM- labelled acetylated peptide as substrate measured by Electrophoretic mobility shift assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1679282Inhibition of HDAC4 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1473161Selectivity ratio of IC50 for recombinant human C-terminal His-tagged/N-terminal Strep2-tagged HDAC8 (1 to 377 residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1882272Inhibition of HDAC1 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1384206Inhibition of HDAC1 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1845772Inhibition of HDAC5 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1917536Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1864665Inhibition of recombinant HDAC2 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1882279Inhibition of HDAC8 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1814013Metal chelating activity assessed as compound-Cu2+ complex formation at 10 to 200 uM incubated for 2 mins followed by pyrocatechol violet addition and further incubated for 10 mins by microplate reader based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1282242Inhibition of recombinant HDAC7 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID767940Inhibition of HDAC4 (unknown origin) using tripeptide MAZ-1675 as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1525777Inhibition of HADC1 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1525776Inhibition of HADC6 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1783133Inhibition of HDAC2 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1355722Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1901780Competitive inhibition of N-terminal His-SUMO tagged zebra fish recombinant HDAC6 catalytic domain 2 transfected with pET28b(+) vector in Escherichia coli BL21 (DE3) RILP cells incubated for 10 mins followed by addition of FITC-M344 measured af ter 10 min2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1718999Stability in mouse liver microsomes assessed as parent compound remaining measured after 30 mins2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1703044Inhibition of recombinant full length human HDAC3 expressed in SF9 baculovirus using FAM- labelled acetylated peptide as substrate measured by Electrophoretic mobility shift assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1141797Selectivity ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1832810Anticancer activity against human HAL-01 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1703055Selectivity ratio of IC50 for full length recombinant human HDAC3 to IC50 for full length recombinant human HDAC62020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1407002Selectivity ratio of IC50 for human recombinant C-terminal His-tagged full length HDAC3/NcoR2 to IC50 for human recombinant N-terminal GST-tagged full length HDAC62018European journal of medicinal chemistry, Sep-05, Volume: 157Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1703046Inhibition of recombinant full length human HDAC8 expressed in SF9 baculovirus using FAM- labelled acetylated peptide as substrate measured by Electrophoretic mobility shift assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1363784Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1282303Inhibition of HDAC6 in human HCT116 cells assessed as upregulation of alpha- tubulin acetylation after 6 hrs by Western blot analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1864674Binding affinity to recombinant HDAC1 (unknown origin) assessed as inhibition constant using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1679289Inhibition of human HDAC2 expressed in Sf9 insect cells using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1282257Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1814034Neuroprotection against mouse model of Alzheimer's disease at 1 mg/kg2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1384809Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in acetylation of alpha-tubulin at 0.1 to 1 uM after 24 hrs by Western blot analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1901765Selectivity ratio of IC50 for full length human recombinant HDAC8 to IC50 for full length human recombinant HDAC62022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1845774Inhibition of HDAC7 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1141786Inhibition of HDAC1 (unknown origin) using RHKK(Ac) (379 to 382) p53 peptide as substrate by fluorescence assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1282248Inhibition of recombinant HDAC9 (unknown origin) using AMC labeled AC-peptide as substrate at 10 uM incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1753635Inhibition of human HDAC6 preincubated for 15 mins followed by substrate addition by fluorescence-based assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1525779Inhibition of HADC3 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1739978Inhibition of HDAC9 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1783134Inhibition of HDAC3 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1882277Inhibition of HDAC6 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1882274Inhibition of HDAC3 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1355690Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1511157Inhibition of HDAC in human HL60 cells assessed as increase in acetylation of H3 at 0.08 to 1.6 uM incubated for 24 hrs by western blot analysis2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1819859Inhibition of full length human HDAC6 using FAM-labeled acetylated peptide as substrate by electrophoretic mobility shift assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
AID1363796Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1849173Inhibition of HDAC6 in human HL-60 cells assessed as increase in Ac-H3 level at 0.9 uM incubated for 24 hrs by immunoblot analysis2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1282233Selectivity ratio of IC50 for human recombinant HDAC8 to IC50 for human recombinant HDAC62016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1882260Inhibition of HDAC6 (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1864727Binding affinity to recombinant HDAC6 (unknown origin) assessed as inhibition constant using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1473146Inhibition of full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1558032Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in release of 7-amino-4-methoxycoumarin using FTS as substrate preincubated for 10 mins followed by substr2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID1739981Inhibition of recombinant human HDAC11 using fluorogenic HDAC substrate class 2a incubated for 30 mins by fluorimetry2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1703047Inhibition of recombinant full length human HDAC11 expressed in SF9 baculovirus using FAM- labelled acetylated peptide as substrate measured by Electrophoretic mobility shift assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1895832Inhibition of HDAC6 (unknown origin) using FTS as substrate pre-incubated with compound for 10 mins followed by substrate addition measured after 30 mins by microtiter plate reader analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
AID1363817Cytotoxicity against human BCP-ALL cells derived from patient 4 after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1141787Inhibition of HDAC2 (unknown origin) using RHKK(Ac) (379 to 382) p53 peptide as substrate by fluorescence assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID767941Inhibition of HDAC3 (unknown origin) using fluorophore tripeptide as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1845771Inhibition of HDAC4 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1739979Inhibition of HDAC6 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1363806Cytotoxicity against human HL60 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1814029Anti-alzheimer activity against amyloid beta (25 to 35) induced working memory deficit mouse assessed as step-through latency time to enter dark compartment at 0.3 to 3 mg/kg, ip administered for 7 days and measured on day 9 days by passive avoidance test2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1703050Inhibition of recombinant full length human HDAC4 expressed in SF9 baculovirus using FAM- labelled acetylated peptide as substrate measured by Electrophoretic mobility shift assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1363809Cytotoxicity against human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1363795Inhibition of HDAC6 in human SEM cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1363797Inhibition of chymotrypsin-like activity of 20S proteasome in human HL60 cells using Suc-LLVY aminoluciferin as substrate after 2 hrs by proteasome-Glo assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1355708Antifungal activity against FLC resistant Candida albicans 100 after 48 hrs by checkerboard microdilution method2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1473156Selectivity ratio of IC50 for full length recombinant human C-terminal GST-tagged HDAC2 to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1849166Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1473149Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to 991 residues) expressed in insect cells using Boc-K(TFA)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1355705Antifungal activity against FLC resistant Candida albicans 0304103 after 48 hrs by checkerboard microdilution method2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1679288Inhibition of HDAC6 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1280285Selectivity ratio of IC50 for class1 HDAC (unknown origin) to IC50 for HDAC6 (unknown origin)2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
AID1864666Inhibition of recombinant HDAC3 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1679279Inhibition of HDAC9 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1355731Protection against spleen enlargement in SCID mouse xenografted with human HEL cells at 10 mg/kg, ip qd2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1282229Inhibition of human recombinant HDAC1 using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1617397Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1532657Inhibition of human HDAC6 using (Z-(Ac)Lys-AMC) as substrate after 90 mins by fluorescence analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID1282256Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID767937Inhibition of HDAC8 (unknown origin) using tripeptide MAZ-1675 as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID767935Inhibition of HDAC9 (unknown origin) using tripeptide MAZ-1675 as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1703045Inhibition of recombinant full length human HDAC6 expressed in SF9 baculovirus using FAM- labelled acetylated peptide as substrate measured by Electrophoretic mobility shift assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1535345Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1864697AUC(0 to infinity) in CD-1 mouse at 5 mg/kg, iv measured after 0.083 to 24 hrs by LC-MS/MS analysis
AID1814024Toxicity in mouse model of Alzheimer's disease assessed as drug tolerability at 0.3 to 3 mg/kg, ip measured after 7 days2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1832806Anticancer activity against human HPBALL cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1723744Selectivity index, ratio of IC50 for inhibition of human recombinant HDAC1 to IC50 for inhibition of human recombinant HDAC62020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
AID1525780Inhibition of HADC8 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1901764Inhibition of full length human recombinant HDAC11 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1813992Inhibition of recombinant HDAC3 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1901805Cytotoxicity against human HD-MB03 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1363787Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1578486Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1901766Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1282255Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID767939Inhibition of HDAC5 (unknown origin) using tripeptide MAZ-1675 as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1441700Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS at 10 uM preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1739976Inhibition of HDAC5 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1428505Selectivity ratio of IC50 for full length human recombinant C-terminal GST-tagged HDAC2 to IC50 for full length human recombinant N-terminal GST-tagged HDAC62017European journal of medicinal chemistry, Feb-15, Volume: 127Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
AID1739972Inhibition of HDAC1 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1363816Cytotoxicity against human BCP-ALL cells derived from patient 3 after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1679290Inhibition of HDAC1 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1473215Antiproliferative activity against human U266 cells after 48 hrs by SRB assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1783135Inhibition of HDAC4 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1890307Inhibition of recombinant human HDAC1 using Boc-Lys-(acetyl)-AMC as substrate incubated for 0.5 hr and measured after 20 mins by fluorescence assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1617402Stability in rat plasma assessed as parent compound remaining at 100 uM after 4 hrs by LC-MS/MS analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1363815Cytotoxicity against human BCP-ALL cells derived from patient 2 after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1558034Selectivity index, ratio of IC50 for recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells to IC50 for recombinant human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected 2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID1876340Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1534493AUC (0 to 24 hrs) in C57BL/6 mouse kidney at 40 mg/kg, po administered via gavage by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1511156Inhibition of HDAC6 in human HL60 cells assessed as increase in acetylation of alpha tubulin at 0.08 to 1.6 uM incubated for 24 hrs by western blot analysis2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
AID1864664Inhibition of recombinant HDAC1 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1200994Selectivity index, ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1679275Inhibition of human sirtuin 2 using fluoro-lysine sirtuin 2 deacetylase as substrate incubated for 60 mins by fluorimetry2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1723743Inhibition of human recombinant HDAC6 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
AID1390013Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1282259Cytotoxicity against human H460 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1363807Cytotoxicity against human SEM cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1679284Selectivity ratio of IC50 for human HDAC2 expressed in Sf9 insect cells to IC50 for HDAC6 (unknown origin)2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1901763Inhibition of full length human recombinant HDAC8 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1876343Inhibition of recombinant full length human HDAC8 expressed in insect Sf9 cells by EMSA analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1718998Stability in human liver microsomes assessed as parent compound remaining measured after 30 mins2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1534443Cytotoxicity against human A549 cells after 72 hrs by MTT assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1917933Inhibition of HDAC6 (unknown origin)2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
AID1282260Cytotoxicity against human A549 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1390010Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence ass2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1473164Selectivity ratio of IC50 for recombinant human N-terminal Strep2-tagged HDAC11 (1 to 347 residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1917544Selectivity index, ratio IC50 for inhibition of HDAC11 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1363814Cytotoxicity against human BCP-ALL cells derived from patient 1 after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1535346Growth inhibition of human U266 cells after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1428507Inhibition of full length human recombinant C-terminal FLAG-tagged HDAC2 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins2017European journal of medicinal chemistry, Feb-15, Volume: 127Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
AID1617413Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1534494AUC (0 to 24 hrs) in C57BL/6 mouse plasma at 40 mg/kg, po administered via gavage by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1849167Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1917530Inhibition of HDAC1 (unknown origin) measured by fluorescence based assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1739973Inhibition of human HDAC2 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1864693Half life in CD-1 mouse at 5 mg/kg, iv measured after 0.083 to 24 hrs by LC-MS/MS analysis
AID1864669Inhibition of recombinant HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1864730Inhibition of HDAC2 (unknown origin) using FTS as substrate preincubated for 6 mins followed by substrate addition measured after 60 secs
AID1814033Cognitive enhancing effect in mouse model of Alzheimer's disease at 1 mg/kg2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1764270Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability for 72 hrs by Celltitre-Glo luminescent assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1814032Anti-alzheimer activity against amyloid beta (25 to 35) induced working memory deficit mouse assessed as step-through latency time to enter dark compartment at 1 mg/kg, ip administered for 7 days and measured on day 9 days in presence of melatonin and fer2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1473157Selectivity ratio of IC50 for full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1200996Selectivity index, ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC6 (unknown origin)2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1876342Inhibition of recombinant full length human HDAC6 expressed in insect Sf9 cells by EMSA analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1753636Inhibition of human HDAC1 preincubated for 15 mins followed by substrate addition by fluorescence-based assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID1882275Inhibition of HDAC4 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1355746In vivo antifungal activity against FLC resistant Candida albicans 0304103 infected in ICR mouse assessed as mouse survival at 5 mg/kg, ip qd up to 20 days (Rvb = 4.5 day)2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1537571Inhibition of HDAC6 (unknown origin)2019MedChemComm, Jul-01, Volume: 10, Issue:7
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1679283Selectivity ratio of IC50 for C-terminal His-tagged human HDAC3/N-terminal GST tagged human NCOR2 to IC50 for HDAC6 (unknown origin)2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1282240Inhibition of recombinant HDAC4 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1679281Inhibition of HDAC5 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1587860Inhibition of dye-labeled tracer binding to HDAC10 (unknown origin) transfected in human HeLa cells measured after 2 hrs by nano-luciferase reporter gene-based BRET assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1679285Selectivity ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1783132Inhibition of HDAC1 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1679274Inhibition of HDAC8 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1355734Antitumor activity in human HEL cells xenografted in SCID mouse assessed as mouse survival time at 10 mg/kg, ip qd2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1473153Inhibition of recombinant human N-terminal Strep2-tagged HDAC11 (1 to 347 residues) expressed in baculovirus infected insect cells using Boc-Lys(TFA)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1864731Inhibition of HDAC3 (unknown origin) using FTS as substrate preincubated for 6 mins followed by substrate addition measured after 60 secs
AID1849172Inhibition of HDAC6 in human HL-60 cells assessed as increase in alpha tubulin acetylation at 0.9 uM incubated for 24 hrs by immunoblot analysis2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID767934Inhibition of HDAC10 (unknown origin)2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1535340Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1282231Inhibition of human recombinant HDAC8 using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1282253Cytotoxicity against human K562 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1532658Selectivity ratio of IC50 for human HDAC1 to IC50 for human HDAC62019European journal of medicinal chemistry, Jan-15, Volume: 162Highly fluorescent and HDAC6 selective scriptaid analogues.
AID1282245Inhibition of recombinant HDAC11 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1814038Inhibition of HDAC3 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate and trypsin addition by microplate reader based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1473150Inhibition of recombinant human C-terminal His-tagged/N-terminal Strep2-tagged HDAC8 (1 to 377 residues) expressed in insect cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1915605Cytotoxicity against human KCL-22 cells2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1441630Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA preincubated for 10 mins followed by substrate addition measured after 10 mins2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1813996Antioxidant activity of compound assessed as trolox equivalent of AAPH radical scavenging activity at 2 to 4 uM preincubated for 15 mins followed by AAPH addition and measured every 2 mins for 90 mins by ORAC-fluorescein assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1355744In vivo antifungal activity against FLC resistant Candida albicans 0304103 infected in ICR mouse assessed as mouse survival at 5 mg/kg, ip qd up to 20 days in co-treated with 1 mg/kg, ip qd fluconazol (Rvb = 4.5 day)2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1617399Selectivity ratio of IC50 for human HDAC2 expressed in baculovirus infected sf9 insect cells to IC50 for human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1864670Inhibition of recombinant HDAC7 (unknown origin) using Boc-Lys (trifluoroacetyl) AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1882281Inhibition of HDAC11 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1901767Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1537570Inhibition of HDAC1 (unknown origin)2019MedChemComm, Jul-01, Volume: 10, Issue:7
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1783138Inhibition of HDAC7 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1739974Inhibition of human C-terminal His-tagged HDAC3 (1 to 428 residues)/human N-terminal GST-tagged NcoR2 (395 to 489 residues) expressed in sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and me2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1617398Selectivity ratio of IC50 for C-terminal His/Flag tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells to IC50 for human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
AID1384209Inhibition of HDAC6 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1917531Selectivity index, ratio IC50 for inhibition of HDAC6 (unknown origin) to IC50 for inhibition of HDAC1 (unknown origin)2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1384207Inhibition of HDAC2 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1864725Binding affinity to recombinant HDAC2 (unknown origin) assessed as inhibition constant using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1917529Inhibition of HDAC6 (unknown origin) measured by fluorescence based assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1578487Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1783137Inhibition of HDAC6 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1525778Inhibition of HADC2 (unknown origin)2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1473159Selectivity ratio of IC50 for recombinant human C-terminal His-tagged HDAC5 (656 to 1122 residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1845769Inhibition of HDAC2 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1141788Inhibition of HDAC6 (unknown origin) using RHKK(Ac) (379 to 382) p53 peptide as substrate by fluorescence assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1282232Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC62016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1849168Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
AID1739977Inhibition of HDAC7 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1679287Cytotoxicity against human MM1.S cells incubated for 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1718995Inhibition of human HDAC6 (unknown origin) using RHKKAc as substrate by fluorescence method2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1282251Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1282250Cytotoxicity against human U266 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1473154Inhibition of recombinant human N-terminal His-tagged SIRT1 (1 to 747 end residues) expressed in Escherichia coli using Ac-RHK-K(Ac)-AMC as substrate after 30 mins in presence of NAD+ by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1814027Anti-alzheimer activity against amyloid beta (25 to 35) induced working memory deficit mouse assessed as increase in spontaneous alternation performance by measuring total number of arm entries at 0.3 mg/kg, ip administered for 7 days and measured on day 2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1473147Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged HDAC4 (627 to 1084 residues) expressed in insect cells using Boc-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1890308Inhibition of recombinant human HDAC6 using Boc-Lys-(acetyl)-AMC as substrate incubated for 0.5 hr and measured after 20 mins by fluorescence assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
AID1473145Inhibition of full length recombinant human C-terminal GST-tagged HDAC2 expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1355689Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1537572Selectivity index, ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC6 (unknown origin)2019MedChemComm, Jul-01, Volume: 10, Issue:7
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
AID1534491AUC (0 to 24 hrs) in C57BL/6 mouse lung at 40 mg/kg, po administered via gavage by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1783136Inhibition of HDAC5 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1355728Antitumor activity against human HEL cells xenografted in BALB/C nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip bid treated for 21 consecutive days relative to control2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1473148Inhibition of recombinant human C-terminal His-tagged HDAC5 (656 to 1122 residues) expressed in insect cells using Boc-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1363786Inhibition of HDAC6 in human SEM cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1917532Antiproliferative activity against human KM12 cells incubated for 72 hrs by CCK-8 assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1363818Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1390012Inhibition of full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate additi2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1473160Selectivity ratio of IC50 for recombinant human N-terminal GST-tagged HDAC7 (518 to 991 residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1282252Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1813993Inhibition of recombinant HDAC6 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1282261Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1355711Antifungal activity against FLC resistant Candida albicans 0710922 after 48 hrs by checkerboard microdilution method2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1473217Antiproliferative activity against human HS5 cells after 48 hrs by SRB assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1845770Inhibition of HDAC3 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1473165Selectivity ratio of IC50 for recombinant human N-terminal His-tagged SIRT1 (1 to 747 end residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1845773Inhibition of HDAC6 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1428508Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins2017European journal of medicinal chemistry, Feb-15, Volume: 127Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
AID1282247Inhibition of recombinant HDAC7 (unknown origin) using AMC labeled AC-peptide as substrate at 10 uM incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1679286Cytotoxicity against human OPM-2 cells incubated for 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1832811Anticancer activity against human REH cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1832808Anticancer activity against human HL-60 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1473214Antiproliferative activity against human RPMI8226 cells after 48 hrs by SRB assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1587859Inhibition of tubastatin-Alexa647-tracer binding to recombinant GST-tagged HDAC10 (unknown origin) measured after 1 hr by TR-FRET assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
AID1864663Selectivity index, ratio of IC50 for recombinant HDAC1(unknown origin) to IC50 for full length recombinant human HDAC6
AID1282301Inhibition of HDAC1/2/3 in human MV4-11 cells assessed as upregulation of histone H3 acetylation at 1000 nM after 6 hrs by Western blot analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1882273Inhibition of HDAC2 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1915604Cytotoxicity against human SEM cells2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1390011Inhibition of full length recombinant human C-terminal His-tagged HDAC2 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1718994Inhibition of LSD1 (unknown origin)2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1282238Inhibition of recombinant HDAC2 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1917542Inhibition of HDAC11 (unknown origin) measured by fluorescence based assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1753637Selectivity index, ratio of IC50 for inhibition of human HDAC1 to IC50 for inhibition of human HDAC62021European journal of medicinal chemistry, Jun-05, Volume: 218Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
AID767942Inhibition of HDAC2 (unknown origin) using fluorophore tripeptide as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1814016Neurotoxicity in mouse HT-22 cells assessed as cell survival at 10 uM incubated for 48 hrs by MTT assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID767938Inhibition of HDAC6 (unknown origin) using fluorophore tripeptide as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1428504Selectivity ratio of IC50 for full length human recombinant C-terminal FLAG-His-tagged HDAC1 to IC50 for full length human recombinant N-terminal GST-tagged HDAC62017European journal of medicinal chemistry, Feb-15, Volume: 127Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
AID1282230Inhibition of human recombinant HDAC6 using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1864689Cmax in CD-1 mouse at 5 mg/kg, iv measured after 0.083 to 24 hrs by LC-MS/MS analysis
AID1864729Inhibition of HDAC1 (unknown origin) using FTS as substrate preincubated for 6 mins followed by substrate addition measured after 60 secs
AID1739975Inhibition of HDAC4 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1363808Cytotoxicity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1814015Metal chelating activity assessed as Fe2+ -ferrozoine complex formation at 10 to 200 uM preincubated for 2 mins followed by ferrozine addition and further incubated for 10 mins by microplate reader based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1473143Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected insect cells using RHK-K(Ac)-AMC as substrate after 90 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1282246Inhibition of recombinant HDAC5 (unknown origin) using AMC labeled AC-peptide as substrate at 10 uM incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1864667Inhibition of recombinant HDAC4 (unknown origin) using Boc-Lys (trifluoroacetyl) AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1718996Inhibition of human HDAC1 at 1uM using RHKKAc as substrate by fluorescence method relative to control2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1363819Antiproliferative activity against human SEM cells at IC50 to 2 times IC50 after 24 to 72 hrs by trypan exclusion method2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1282258Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1679277Inhibition of human sirtuin 1 using fluorogenic HDAC substrate incubated for 20 mins by fluorimetry2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1282262Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1363810Cytotoxicity against imatinib-resistant human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1384208Inhibition of HDAC3 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
AID1845776Inhibition of HDAC9 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1718997Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability after 144 hrs2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1703043Cytotoxicity against human MRC9 cells measured after 72 hrs by spectrophotometer method2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1441632Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 50 uM by SYPRO orange dye-based thermofluor assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1363812Cytotoxicity against human RPMI18226 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1917533Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK-8 assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1384810Inhibition of class 1 HDAC in human SH-SY5Y cells assessed as increase in acetylation of histone H3 at 0.1 to 1 uM after 24 hrs by Western blot analysis2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
AID1282243Inhibition of recombinant HDAC9 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1363813Cytotoxicity against human U266 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1282297Inhibition of HDAC6 in human MV4-11 cells assessed as upregulation of alpha- tubulin acetylation after 6 hrs by Western blot analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1845768Inhibition of HDAC1 (unknown origin) using FTS as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1282249Inhibition of recombinant HDAC11 (unknown origin) using AMC labeled AC-peptide as substrate at 10 uM incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1363785Inhibition of HDAC6 in human HL60 cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1917535Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CCK-8 assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1473151Inhibition of HDAC9 (unknown origin)2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1783139Inhibition of HDAC8 (unknown origin)2021European journal of medicinal chemistry, Oct-05, Volume: 221Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
AID1813994Selectivity ratio of IC50 for recombinant HDAC3 (unknown origin) to IC50 for recombinant HDAC6 (unknown origin)2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1703056Inhibition of N-terminal 6 His-SUMO tagged Zebrafish HDAC6 CD2 domain expressed in Escherichia coli BL21(DE3) RILP pretreated for 10 mins before FITC-M344 addition and measured after 10 mins by fluorescence polarization competition assay2020European journal of medicinal chemistry, Sep-01, Volume: 201PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
AID1901762Inhibition of full length human recombinant HDAC6 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1282244Inhibition of recombinant HDAC10 (unknown origin) using AMC labeled AC-peptide as substrate incubated for 1 hr by fluorescence analysis2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1406980Selectivity ratio of IC50 for human recombinant C-terminal His/FLAG-tagged full length HDAC1 to IC50 for N-terminal GST-tagged full length HDAC62018European journal of medicinal chemistry, Sep-05, Volume: 157Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1535339Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma.
AID1917528Inhibition of PI3Kdelta (unknown origin) measured by ADP-Glo assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1876339Cytotoxicity against human MRC9 cells assessed as cell viability incubated for 72 hrs by Cell titer- blue assay2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1832807Anticancer activity against human TALL-1 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1814014Metal chelating activity compound-Zn2+ complex formation at 10 to 200 uM preincubated for 2 mins followed by di-thizone addition by microplate reader based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1901786Binding affinity to full length HDAC6-NanoLuc fusion protein (unknown origin) expressed in HeLa cells assessed as residence time by NanoBRET assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1390009Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID767936Inhibition of HDAC7 (unknown origin) using tripeptide MAZ-1675 as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1473158Selectivity ratio of IC50 for recombinant human C-terminal His-tagged/N-terminal GST-tagged HDAC4 (627 to 1084 residues) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1390014Inhibition of full length recombinant human C-terminal His-tagged HDAC8 expressed in baculovirus infected sf9 cells using Boc-Lys-(TFA)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1901768Cytotoxicity against human MRC9 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1390015Selectivity ratio of IC50 for full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells to IC50 for full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
AID1719020Antitumour activity against human MM1.S cells xenografted in SCID mouse assessed as tumour growth inhibition at 50 mg/kg, ip for 12 days relative to control2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
AID1363798Inhibition of chymotrypsin-like activity of 20S proteasome in human SEM cells using Suc-LLVY aminoluciferin as substrate after 2 hrs by proteasome-Glo assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1917534Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK-8 assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1845775Inhibition of HDAC8 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition by microtiter plate reader assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
AID1679278Inhibition of human HDAC11 using fluorogenic HDAC substrate incubated for 30 mins by fluorimetry2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1441699Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1441631Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1355691Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1355723Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1917543Selectivity index, ratio IC50 for inhibition of HDAC8 (unknown origin) to IC50 for inhibition of HDAC6 (unknown origin)2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1407001Selectivity ratio of IC50 for human recombinant C-terminal His/FLAG-tagged full length HDAC2 to IC50 for human recombinant N-terminal GST-tagged full length HDAC62018European journal of medicinal chemistry, Sep-05, Volume: 157Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
AID1723742Inhibition of human recombinant HDAC1 using ZMAL (Z-Lys(Ac)-AMC) fluorogenic substrate incubated for 90 mins by fluorescence based assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
AID1813995Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition by microplate reader based assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1882280Inhibition of HDAC9 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1864668Inhibition of recombinant HDAC5 (unknown origin) using Boc-Lys (trifluoroacetyl) AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1534492AUC (0 to 24 hrs) in C57BL/6 mouse liver at 40 mg/kg, po administered via gavage by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
AID1363799Inhibition of chymotrypsin-like activity of 20S proteasome in imatinib-resistant human SUP-B15 cells using Suc-LLVY aminoluciferin as substrate after 2 hrs by proteasome-Glo assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1141798Selectivity ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC6 (unknown origin)2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
AID1876344Inhibition of recombinant full length HDAC11 (unknown origin) expressed in insect Sf9 cells by EMSA analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
AID1901761Inhibition of full length human recombinant HDAC3 expressed in Sf9 baculovirus system using FAM-labeled acetylated peptide as substrate by measuring fluorescence intensity by EMSA method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of HDAC6-Selective Inhibitor NN-390 with
AID1428506Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins2017European journal of medicinal chemistry, Feb-15, Volume: 127Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
AID767943Inhibition of HDAC1 (unknown origin) using fluorophore tripeptide as substrate after 30 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
AID1363794Inhibition of HDAC6 in human HL60 cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1473162Selectivity ratio of IC50 for HDAC9 (unknown origin) to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1363842Inhibition of HDAC6 in human SEM cells assessed as decrease in aggresome accumulation at 1.6 uM after 18 hrs by FACS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1864672Inhibition of recombinant HDAC9 (unknown origin) using Boc-Lys (trifluoroacetyl) AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1363838Inhibition of HDAC6 in human SEM cells assessed as decrease in aggresome accumulation at IC50 after 18 hrs by fluorescence microscopic method2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1814037Anti-alzheimer activity against amyloid beta (25 to 35) induced working memory deficit in mouse assessed as increase in spontaneous alternation performance at 1 mg/kg, ip administered for 7 days and measured on day 8 by Y-maze test2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
AID1864671Inhibition of recombinant HDAC8 (unknown origin) using Boc-Lys (trifluoroacetyl) AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1363782Inhibition of HDAC6 in human HL60 cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1558033Inhibition of recombinant human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells assessed as decrease in release of 7-amino-4-methoxycoumarin using FTS as substrate preincubated for 10 mins followed by substrate a2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
AID1739983Inhibition of HDAC8 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs and measured over 30 mins2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1864726Binding affinity to recombinant HDAC3 (unknown origin) assessed as inhibition constant using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based microplate reader analysis
AID1200995Selectivity index, ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC6 (unknown origin)2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
AID1473155Selectivity ratio of IC50 for full length recombinant human C-terminal FLAG/His-tagged HDAC1 to IC50 for full length recombinant human N-terminal GST-tagged HDAC62018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1864732Inhibition of HDAC6 (unknown origin) using FTS as substrate preincubated for 6 mins followed by substrate addition measured after 60 secs
AID1363783Inhibition of HDAC6 in human SEM cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
AID1355724Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
AID1473144Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
AID1764269Inhibition of Class 1/2b HDAC in human HL-60 cells by HDAC-Glo assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1832819Induction of apoptosis in human K562 cells assessed as apoptosis at 6 uM after 24 to 72 hrs using annexin V/PI followed by flow cytometry2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1917541Inhibition of HDAC8 (unknown origin) measured by fluorescence based assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.
AID1882278Inhibition of HDAC7 (unknown origin) using fluorescent peptide substrate2022European journal of medicinal chemistry, Feb-05, Volume: 229Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
AID1679280Inhibition of HDAC7 (unknown origin) using MAZ-1675 as substrate preincubated for 10 mins followed by substrate addition and shaken for 60 secs2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent advances in the discovery of potent and selective HDAC6 inhibitors.
AID1282237Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1282295Toxicity in NOD/SCID mouse xenografted with human Ramos cells assessed as death at 40 mg/kg, po q2d for 6 days2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346134Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs))2012Blood, Mar-15, Volume: 119, Issue:11
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
AID1346068Human histone deacetylase 8 (3.5.1.- Histone deacetylases (HDACs))2012Blood, Mar-15, Volume: 119, Issue:11
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
AID1346082Human histone deacetylase 2 (3.5.1.- Histone deacetylases (HDACs))2012Blood, Mar-15, Volume: 119, Issue:11
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
AID1346032Human histone deacetylase 6 (3.5.1.- Histone deacetylases (HDACs))2012Blood, Mar-15, Volume: 119, Issue:11
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
AID1346077Human histone deacetylase 3 (3.5.1.- Histone deacetylases (HDACs))2012Blood, Mar-15, Volume: 119, Issue:11
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (116)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's63 (54.31)24.3611
2020's53 (45.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.30 (24.57)
Research Supply Index4.78 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index33.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.85%)5.53%
Reviews9 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other107 (91.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]